Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L G Paz-Ares

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Genitourinary malignanciesL G Paz-Ares, M R Smith
British Journal of Cancer|November 25, 2010
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabA Gualberto, M L Hixon, D D Karp, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2014
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsG V Scagliotti, C Gridelli, F de Marinis, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisH Borghaei, T-E Ciuleanu, J-S Lee, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Genitourinary malignanciesL G Paz-Ares, M R Smith
British Journal of Cancer|November 25, 2010
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabA Gualberto, M L Hixon, D D Karp, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2014
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsG V Scagliotti, C Gridelli, F de Marinis, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisH Borghaei, T-E Ciuleanu, J-S Lee, et al.
Pageof 1